Abstract
Host genetic variants can determine the susceptibility to COVID-19 infection and severity as noted in a recent Genome-wide Association Study (GWAS) by Pairo-Castineira et al.1. Given the prominent genetic differences in Indian sub-populations as well as differential prevalence of COVID-19, here, we deploy the previous study and compute genetic risk scores in different Indian sub-populations that may predict the severity of COVID-19 outcomes in them. We computed polygenic risk scores (PRSs) in different Indian sub-populations with the top 100 single-nucleotide polymorphisms (SNPs) with a p-value cutoff of 10−6 derived from the previous GWAS summary statistics1. We selected SNPs overlapping with the Indian Genome Variation Consortium (IGVC) and with similar frequencies in the Indian population. For each population, median PRS was calculated, and a correlation analysis was performed to test the association of these genetic risk scores with COVID-19 mortality. We found a varying distribution of PRS in Indian sub-populations. Correlation analysis indicates a positive linear association between PRS and COVID-19 deaths. This was not observed with non-risk alleles in Indian sub-populations. Our analyses suggest that Indian sub-populations differ with respect to the genetic risk for developing COVID-19 mediated critical illness. Combining PRSs with other observed risk-factors in a Bayesian framework can provide a better prediction model for ascertaining high COVID-19 risk groups. This has a potential utility in the design of more effective vaccine disbursal schemes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funds from intramural seed grant to IG of IITD and in part by a grant from the Department of Biotechnology (DBT) and the Govt. of India - [DBT/GenomeIndia/2018] and a CSIR grant [GAP0206].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No patient or participant was involved in the study. Already available genotype data, summary stats and COVID-19 statistics have been applied and used in the bioinformatic analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
For all our analyses, we used the summary statistics available at https://genomicc.org/data. The COVID-19 data for the Indian population was retrieved from ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20130502/, https://www.covid19india.org/, https://covid19.Assam.gov.in/district/, https://github.com/covid19india/api. The codes used for the study can be accessed at the following GitHub repository : https://github.com/Prakrithi-P/COVID_PRS_IGV.
